Abstract
In this article we will analyse the framework of laws and regulations behind the pricing system in France as well as the way in which prices are fixed by the Economic Committee for Health Products following the opinion of the Transparency Commission on the reimbursable nature of those medicines. Quite apart from these two topics, it is interesting to analyse the increasingly important role of the new structures regulating the prices of those drugs. Opinions are, to say the least, divided as to whether such a complex system, when viewed from the outside, meets the objective set by the French Administration and whether a trend towards more European pricing structures is now emerging.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
